Skip to main content
. Author manuscript; available in PMC: 2020 Nov 14.
Published in final edited form as: Leukemia. 2020 May 14;34(11):2981–2991. doi: 10.1038/s41375-020-0858-1

Figure 4. The combination of dasatinib and quizartinib suppresses stroma-enhanced glycolysis in a STAT5-independent manner in FLT3-ITD+ AML.

Figure 4.

A. Glycolysis and glycolytic capacity were measured in MOLM-13 cells cultured in RM or CM and treated with quizartinib ± dasatinib for 24 hours. (n=3) B. Glycolysis and glycolytic capacity were measured in MOLM-13 cells expressing a doxycycline-inducible shRNA against STAT5. Cells were cultured in CM ± doxycycline (DOX) and treated with quizartinib and/or dasatinib for 24 hours. (n=3)